Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction
Lijnen, P.; Boelaert, J.; van Eeghem, P.; Daneels, R.; Schurgers, M.; de Jaegere, P.; van der Stichele, E.; Vincke, J.; Fagard, R.; Verschueren, L.J.; Amery, A.
Clinical Nephrology 19(3): 143-146
1983
ISSN/ISBN: 0301-0430 PMID: 6340878 Document Number: 212591
Patients (29) with recent myocardial infarction were randomly allocated to a placebo group (n = 14) and to a group (n = 15) who received sulfinpyrazone, 4 .times. 200 mg daily for 7 days. Renal function significantly and transiently deteriorated in the sulfinpyrazone group compared to the placebo group. In the sulfinpyrazone group the 24 h urinary prostaglandin E2 and kallikrein excretion were suppressed. The decrease in renal function caused by sulfinpyrazone early after myocardial infarction may be mediated by an inhibition of renal prostaglandin and/or kallikrein-kinin synthesis.